Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 1636 AL 1650

Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial

Cicchetti F, David LS, Siddu A, Denis HL.

Neurobiol Dis. 2019 Oct;130:104530. doi: 10.1016/j.nbd.2019.104530. Epub 2019 Jul 10.

A Review of the Molecular Mechanisms of Traumatic Brain Injury

Ladak AA, Enam SA, Ibrahim MT.

World Neurosurg. 2019 Nov;131:126-132. doi: 10.1016/j.wneu.2019.07.039. Epub 2019 Jul 10.

Brain impedance variation of directional leads implanted in subthalamic nuclei of Parkinsonian patients

Eleopra R, Rinaldo S, Devigili G, Lettieri C, Mondani M, D'Auria S, Piacentino M, Pilleri M.

Clin Neurophysiol. 2019 Sep;130(9):1562-1569. doi: 10.1016/j.clinph.2019.06.001. Epub 2019 Jun 22.

The role of one-carbon metabolism and homocysteine in Parkinson's disease onset, pathology and mechanisms

Murray LK, Jadavji NM.

Nutr Res Rev. 2019 Dec;32(2):218-230. doi: 10.1017/S0954422419000106. Epub 2019 Jul 15.

Using Drosophila as a platform for drug discovery from natural products in Parkinson's disease

Maitra U, Ciesla L.

Medchemcomm. 2019 Apr 30;10(6):867-879. doi: 10.1039/c9md00099b. eCollection 2019 Jun 1.

Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders

Stroud C, Onnela JP, Manji H.

NPJ Digit Med. 2019 Jun 3;2:44. doi: 10.1038/s41746-019-0123-z. eCollection 2019.

Vascular Parkinsonism by Infarctions at Different Locations on 18F-FP-CIT PET/CT

Kim C, Kim DY, Hong IK.

Clin Nucl Med. 2019 Nov;44(11):e627-e628. doi: 10.1097/RLU.0000000000002721.

Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations

Modi NB, Mittur A, Dinh P, Rubens R, Gupta S.

Clin Neuropharmacol. 2019 Sep/Oct;42(5):149-156. doi: 10.1097/WNF.0000000000000354.

Misconceptions about speech impairment in Parkinson's disease

Moreau C, Pinto S.

Mov Disord. 2019 Oct;34(10):1471-1475. doi: 10.1002/mds.27791. Epub 2019 Jul 15.

Hallucinations, somatic-functional disorders of PD-DLB as expressions of thalamic dysfunction

Onofrj M, Espay AJ, Bonanni L, Delli Pizzi S, Sensi SL.

Mov Disord. 2019 Aug;34(8):1100-1111. doi: 10.1002/mds.27781. Epub 2019 Jul 15.

Pure autonomic failure

Kabir MA, Chelimsky TC.

Handb Clin Neurol. 2019;161:413-422. doi: 10.1016/B978-0-444-64142-7.00064-3.

Selecting candidates for Deep Brain Stimulation in Parkinson's disease: the role of patients' expectations

Geraedts VJ, Kuijf ML, van Hilten JJ, Marinus J, Oosterloo M, Contarino MF.

Parkinsonism Relat Disord. 2019 Sep;66:207-211. doi: 10.1016/j.parkreldis.2019.07.011. Epub 2019 Jul 10.

Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease

Fava VM, Xu YZ, Lettre G, Van Thuc N, Orlova M, Thai VH, Tao S, Croteau N, Eldeeb MA, MacDougall EJ, Cambri G, Lahiri R, Adams L, Fon EA, Trempe JF, Cobat A, Alcaïs A, Abel L, Schurr E.

Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15616-15624. doi: 10.1073/pnas.1901805116. Epub 2019 Jul 15.

[Early oral symptoms of Parkinson's disease]

Jager DHJ, Verhoeff MC, van Dijk KD, de Baat C.

Ned Tijdschr Tandheelkd. 2019 Jul;126(7-8):363-368. doi: 10.5177/ntvt.2019.07/08.19033.

Propagation of Tau via Extracellular Vesicles

Pérez M, Avila J, Hernández F.

Front Neurosci. 2019 Jul 2;13:698. doi: 10.3389/fnins.2019.00698. eCollection 2019.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias